| Nr. | Year OPEN | Title | users say | rate good | rate bad | no link | Citation |
|---|
Drotrecogin alphaSepsis| 1 | 2003 | Role of activated protein C in the pathophysiology of severe sepsis. | 
| + | - | nl | Am J Crit Care 12(6):518-24; quiz 525-6 (2003) |
| 2 | 2008 | Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated). |
| + | - | nl | Crit Care 12(2):R45 (2008) |
| 3 | 2007 | Practical aspects of treatment with drotrecogin alfa (activated). |
| + | - | nl | Crit Care 11 Suppl 5(-):S7 (2007) |
| 4 | 2007 | The safety profile of drotrecogin alfa (activated). |
| + | - | nl | Crit Care 11 Suppl 5(-):S6 (2007) |
| 5 | 2007 | Clinical trials in severe sepsis with drotrecogin alfa (activated). |
| + | - | nl | Crit Care 11 Suppl 5(-):S5 (2007) |
| 6 | 2007 | The protein C pathway: implications for the design of the RESPOND study. |
| + | - | nl | Crit Care 11 Suppl 5(-):S4 (2007) |
| 7 | 2007 | Recombinant human activated protein C: current insights into its mechanism of action. |
| + | - | nl | Crit Care 11 Suppl 5(-):S3 (2007) |
| 8 | 2007 | Recombinant activated protein C in sepsis: endothelium protection or endothelium therapy? |
| + | - | nl | Crit Care 11(1):103 (2007) |
| 9 | 2003 | Clinical review: Drotrecogin alfa (activated) as adjunctive therapy for severe sepsis--practical aspects at the bedside and patient identification. |
| + | - | nl | Crit Care 7(6):445-50 (2003) |
| 10 | 2007 | Drotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysis. |
| + | - | nl | BMC Anesthesiol 7(-):5 (2007) |
| 11 | 2006 | Treatment of severe sepsis: where next? Current and future treatment approaches after the introduction of drotrecogin alfa. |
| + | - | nl | Vasc Health Risk Manag 2(1):3-18 (2006) |
| 12 | 2009 | Growing insights into the potential benefits and risks of activated protein C administration in sepsis: a review of preclinical and clinical studies. |
| + | - | nl | Biologics 3(-):391-406 (2009) |
| 13 | 2005 | Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis in adults: a systematic review and economic evaluation. |
| + | - | nl | Health Technol Assess 9(11):1-126, iii-iv (2005) |
| 14 | 2009 | Modulation of sepsis outcome with variants of activated protein C. |
| + | - | nl | J Thromb Haemost 7 Suppl 1(-):127-31 (2009) |
| 15 | 2007 | Activated protein C. |
| + | - | nl | J Thromb Haemost 5 Suppl 1(-):73-80 (2007) |
| 16 | 2004 | Activated protein C in sepsis. |
| + | - | nl | J Thromb Haemost 2(5):708-17 (2004) |
| 17 | 2003 | Drotrecogin alfa (activated): a novel therapeutic strategy for severe sepsis. |
| + | - | nl | Postgrad Med J 79(927):5-10 (2003) |
| 18 | 2009 | Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study. |
| + | - | nl | Am J Respir Crit Care Med 180(9):861-6 (2009) |
| 19 | 2007 | Activated protein C: cost-effective or costly? |
| + | - | nl | Crit Care 11(5):164 (2007) Brar SS |
| 20 | 2009 | Treatment of septic shock and use of drotrecogin alfa (activated) in children. | 
| + | - | nl | Expert Rev Anti Infect Ther 7(7):769-72 (2009) |
